Bilgehan Aygen

Bilgehan Aygen

Auto-generated profile, based on publicly available information

Bilgehan Aygen

Department of Infectious Diseases and Clinical Microbiology, Erciyes University School of Medicine, Kayseri, Turkey

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2018 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
BABilgehan Aygen
Bilgehan Aygen
ADAhmet Muzaffer Demir
Ahmet Muzaffer Demir
MGMahmut Gumus
Mahmut Gumus
OKOguz Karabay
Oguz Karabay
SKSabahattin Kaymakoğlu
Sabahattin Kaymakoğlu
FTFehmi Tabak
Fehmi Tabak
This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to an emergency risk of hepatitis B reactivation. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions. Cite this article as: Aygen B, Demir AM, Gümüş M, et al. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turk J Gastroenterol 2018; 29: 259-69.

1 October 2001 in Journal of Hospital Infection
Verified
Journal Article
Closed access
MDMehmet Doganay
Mehmet Doganay
BAB. Aygen
B. Aygen
DED. Ešel
D. Ešel

10 November 2021 in Klimik Dergisi/Klimik Journal
Verified
Journal Article
Closed access
BUBurcu Uysal
Burcu Uysal
NMNecati Mumcu
Necati Mumcu
OYOrhan Yıldız
Orhan Yıldız
BABilgehan Aygen
Bilgehan Aygen
Objective: The aim of the present study was to compare the new serological tests “immuncapture agglutination” (Brucellacapt, Vircell, Granada, Spain), enzyme-linked immunosorbent assay (ELISA) and the classical tests for diagnosis of acute, subacute or chronic brucellosis. Methods: Forty-nine samples of patients who presented with fever and clinical suspicion of brucellosis and who were admitted to Infectious Disease Department of Erciyes University Hospital with agglutination (SAT) titers ≥1/10 were collected during 2010 and 2012. And 30 healthy volunteers were enrolled in the study. All samples were subjected to the Brucella spp. Spesific culture, STA test, Brucellacapt test and ELISA for detection of IgM, IgA, and IgG. Coombs test was performed for 28 samples with titers <1/160 as measured by STA. Cohen’s kappa test was used to evaluate the correlation between the tests. Results: Blood culture was positive in 6 (12, 2%), joint fluid culture in 2 (4%), STA test in 21 (42, 8%), Brucellacapt test in 36 (73.4%), ELISA IgG in 33 (67.3%), ELISA IgM in 33 (67.3%), ELISA IgA in 31 (61.2%) of 49 patients. While STA, brucellacapt ve ELISA IgA tests were negative in all of the control group (n=30), in four individuals (%13.3) ELISA IgG, three individuals (%10) ELISA IgM were found low positive. When STA test was taken as the reference method, the sensitivities were found to be 100% in brucellacapt test, 85.7%, 90.4%, 90.% in ELISA IgG, IgM, IgA respectively and 23.8% in blood culture. Specifities were 74.1%, 67.2%, 67.2%, 79.3% and 98.2% respectively. When presence of clinical findings are taken as a reference, brucellacapt test was found to be most compatible (κ=0,66). Conclusions: STA was found to be unsatisfactory in the diagnosis of brucellosis in patients. Brucellacapt and/or ELISA tests are suggested to be used to verify results of STA.

9 October 2023 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
FIFeyza İzCi
Feyza İzCi
Zeynep ... TureZeynep ... Ture
Zeynep ... Ture
GDGokcen Dinc
Gokcen Dinc
AYArzu Yay
Arzu Yay
EEEsma Eryilmaz-Eren
Esma Eryilmaz-Eren
BABilgehan Aygen
Bilgehan Aygen

15 April 2023 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
Zeynep ... TureZeynep ... Ture
Zeynep ... Ture
OYOrhan Yıldız
Orhan Yıldız
OYOzan Yaman
Ozan Yaman
GUGamze Kalın Unuvar
Gamze Kalın Unuvar
BABilgehan Aygen
Bilgehan Aygen
Malaria continues to be a global public health problem considering the number of cases and death rate worldwide. There were no domestic cases reported from our country in the World Health Organization 2021 malaria report. All the 200-250 annual cases reported from our country have a history of travel to the endemic region. In this report, three malaria cases caused by Plasmodium falciparum and Plasmodium vivax in Kayseri province without a history of travel to the endemic region were presented. The first case was an 18-year-old male patient with no known chronic disease. He admitted to the hospital with the complaint of high fever reaching 40°C, which continued for two days, increased with chills and decreased with sweating. Physical examination revealed hepatosplenomegaly and laboratory results revealed thrombocytopenia. Species identification was made by real-time polymerase chain reaction (Rt-PCR) method in the patient with ring-shaped trophozoites in the peripheral smear. Artemether-lumefantrine and primaquine treatments were given to the patient with mixed parasitemia of P.falciparum and P.vivax. One and two days after the admission, the second and third cases also admitted with similar complaints. Mixed parasitemia was observed in all three patients who did not have a history of traveling abroad. After the antiparasitic treatment, the patients improved clinically and laboratory, and no recurrent parasitemia was observed. With the occurrence of these cases, efforts to combat vectors were initiated throughout the province. In conclusion, the presence of anopheles mosquitoes and imported cases still poses a risk for domestic malaria cases. In patients who do not have a history of traveling abroad, malaria should be considered in the clinical preliminary diagnosis and species identification should be made by methods such as Rt-PCR in order to give appropriate treatments.

9 December 2023 in Klimik Dergisi/Klimik Journal
Verified
Journal Article
Open access
BABilgehan Aygen
Bilgehan Aygen
YGYunus Gurbuz
Yunus Gurbuz
RCRiza Aytac Cetinkaya
Riza Aytac Cetinkaya
GCGule Cinar
Gule Cinar
UKUner Kayabas
Uner Kayabas
NDNese Demirturk
Nese Demirturk
Direct-acting antiviral (DAA) drugs have increased the effectiveness of treatment in hepatitis C patients. With the developments in the world and DAA drugs coming into use in our country, the consensus report on the management of hepatitis C virus (HCV) infection has needed to be updated. It was first published in 2014 and updated in 2017 by the Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases. Here, the Study Group has reviewed every aspect of chronic hepatitis C and revised the consensus report with the updated information. At the end of each topic, the agreed recommendations are summarized, considering the drugs reimbursed in our country.